Etelcalcetide

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: August 17, 2026

Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders.

Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders.

Journal: Cureus

Published: June 17, 2026

Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential.

Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential.

Journal: Frontiers in immunology

Published: June 17, 2026

Combining dietary fiber inulin with parathyroid hormone-lowering therapy improves bone remodeling and mechanics in a rat model of Chronic Kidney Disease-Mineral Bone Disorder.

Combining dietary fiber inulin with parathyroid hormone-lowering therapy improves bone remodeling and mechanics in a rat model of Chronic Kidney Disease-Mineral Bone Disorder.

Journal: Kidney international

Published: January 14, 2026

FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.

FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.

Journal: Drug development research

Published: December 23, 2025

Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.

Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.

Journal: Clinical nephrology

Published: November 27, 2025

The calcimimetic etelcalcetide attenuates pressure overload-induced cardiac hypertrophy in rats with and without chronic kidney disease.

The calcimimetic etelcalcetide attenuates pressure overload-induced cardiac hypertrophy in rats with and without chronic kidney disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 21, 2025

The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.

The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.

Journal: Clinical nephrology

Published: August 20, 2025

Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.

Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.

Journal: Renal failure

Published: July 03, 2025

QSPR analysis of the drugs used to treat renal failure and its complications using degree and modified reverse degree indices.

QSPR analysis of the drugs used to treat renal failure and its complications using degree and modified reverse degree indices.

Journal: Scientific reports

Published: June 25, 2025

Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database.

Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database.

Journal: Journal of pharmaceutical policy and practice

Published: April 02, 2025

Combination Treatment With Intravenous and Oral Calcimimetics for Secondary Hyperparathyroidism in Hemodialysis Patients Who Decline Parathyroidectomy.

Combination Treatment With Intravenous and Oral Calcimimetics for Secondary Hyperparathyroidism in Hemodialysis Patients Who Decline Parathyroidectomy.

Journal: Cureus

Published: March 30, 2025

Showing 1-12 of 144

Last Updated: 09/26/2026